Beware ketoacidosis with SGLT2 inhibitors in latent autoimmune diabetes.

Link to article at PubMed

Related Articles

Beware ketoacidosis with SGLT2 inhibitors in latent autoimmune diabetes.

Am J Med. 2020 Jan 07;:

Authors: Nolan BJ, Varadarajan S, Fourlanos S, Neoh SL

Abstract
BACKGROUND: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are increasingly used for the treatment of type 2 diabetes but have been associated with ketoacidosis.
METHODS/RESULTS: We report a case series of three patients with latent autoimmune diabetes who presented with ketoacidosis, including one case with normal blood glucose levels, in the context of SGLT2 inhibitor use.
CONCLUSIONS: SGLT2 inhibitors should only be used with caution and close clinical monitoring in patients with latent autoimmune diabetes. A clinical risk score permits targeted autoantibody testing and should be undertaken prior to commencement of SGLT2 inhibitors and/or cessation of insulin.

PMID: 31923401 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published.